Oxymetazoline safe, effective for facial erythema of rosacea
Oxymetazoline cream 1% appears to be safe, tolerable and effective for treating moderate-to-severe persistent erythema of rosacea, according to a recent study.
After a 52-week study period, an increasing number of patients showed ≥2-grade improvement in the composite of Clinician Erythema Assessment and Subject Self-Assessment scores 3–6 hours after application of cream relative to baseline. This indicated continued efficacy of oxymetazoline.
In terms of safety, less than half of the participants (43.6 percent) reported treatment-emergent adverse effects (TEAEs), and most were moderate or mild in severity. Only 3.4 percent of the cohort developed serious AEs, none of which were related to the treatment or led to discontinuation.
The incidence rate of TEAE was 8.2 percent, and the most common were application-site dermatitis, pain, paresthesia and pruritus. Only three cases of application-site dermatitis and one case each of pain, erythema and photosensitivity were considered severe. All other cases of TEAEs were mild or moderate.
Moreover, the mean inflammatory lesion count dropped from 3.5 at baseline to 1.5–2.9 at all post-treatment timepoints. Overall, 38.4 percent of the participants showed a ≥1-grade worsening of disease severity from baseline as related to inflammatory lesions.
For the study, researchers recruited 440 adults (mean age 53.1±11.4 years; 76.1 percent female) with mild-to-severe persistent facial erythema of rosacea. Those with facial hairs, tattoos or other characteristics that would interfere with erythema assessment were excluded. Oxymetazoline was applied topically on the face once daily for 52 days.